RxDoctor Payments Data

Robert Habig

Family Medicine · Carmel, INNPI 1083799977

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 576 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,999 and has fallen 64.3% since, to $715 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,858in general payments, 2019–2025

Across 576 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$823
  • AstraZeneca$721
  • Bayer$570
  • Boehringer Ingelheim$408
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,858 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana →

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$43,176
JardianceEmpagliflozin20$34,818
FarxigaDapagliflozin Propanediol19$28,168
EliquisApixaban20$23,922
JanuviaSitagliptin Phosphate13$21,634
ArexvyRsvpref3 Antigen/As01e/Pf11$3,394
Atorvastatin Calcium164$1,437
Levothyroxine Sodium163$1,417
Tamsulosin Hcl56$989
Nebivolol Hcl35$959
Omeprazole44$937
Rosuvastatin Calcium94$915
Celecoxib29$800
Simvastatin77$687
Metformin Hcl57$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$823$43,17638 claims
Boehringer IngelheimJardiance$408$34,81820 claims
AstraZenecaFarxiga$721$28,16819 claims
PfizerEliquis$198$23,92220 claims
MerckJanuvia$51$21,63413 claims
GSKArexvy$239$3,39411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,417163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Carmel

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →